Wide Ranks

AKTX

Akari Therapeutics Plc

1.12

Top Statistics
Market Cap 27 M Forward PE -0.3294 Revenue Growth 0.00 %
Current Ratio 0.58 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1943.37 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 4 M Total Cash Per Share Total Debt 1000000
Total Debt To Equity Current Ratio 0.58 Book Value Per Share -0.0350
All Measures
Short Ratio 192.00 % Message Board Id finmb_306632341 Fax 929 274 7553
Shares Short Prior Month 39049 City Boston Uuid 7ad3d9ad-13c2-3784-92d6-18475fbe0a3b
Previous Close 1.14 First Trade Date Epoch Utc 1 B Book Value -0.0350
Beta 0.9510 Total Debt 1000000 Volume 42279
Last Split Date 1 B Fifty Two Week Low 0.9000 Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Net Income To Common -20133000
Short Percent Of Float 0.0023 Implied Shares Outstanding 5 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 117370 Average Volume10days 117370
Total Cash 4 M Next Fiscal Year End 1 B Held Percent Insiders 0.1191
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.14 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.42 Open 1.12 Free Cashflow -7512510
State MA Dividend Yield 0.00 % Return On Assets -1.73
Time Zone Short Name EST Trailing Eps -2.58 Day Low 1.07
Address1 22 Boston Wharf Road Shares Outstanding 24 M Price Hint 4
Target High Price 0.0000 Website https://www.akaritx.com 52 Week Change -0.6203
Average Volume 31190 Forward Eps -3.40 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 47.60 % Last Split Factor 1:20
Regular Market Day High 1.15 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 4.40 Day High 1.15 Shares Short 21291
Regular Market Open 1.12 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0018 Operating Cashflow -15796000
Currency USD Time Zone Full Name America/New_York Market Cap 27 M
Is_nasdaq_100 False Zip 02210 Quote Type EQUITY
Industry Biotechnology Long Name Akari Therapeutics, Plc Regular Market Day Low 1.07
Held Percent Institutions 0.0051 Current Price 1.12 Address2 Floor 7
Enterprise To Ebitda -1943.37 Financial Currency USD Current Ratio 0.58
Industry Disp Biotechnology Country United States Float Shares 10 B
Two Hundred Day Average 2.51 Enterprise Value 35 B Forward PE -0.3294
Regular Market Volume 42279 Ebitda -18082000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.

Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.

The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.

The company is headquartered in Boston, Massachusetts.